Screener
Gyre Therapeutics, Inc. GYRE Gyre — Selling General And Administrative Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Gyre Pharmaceuticals | Gyre | Total |
|---|---|---|---|
| Selling and marketing | 13,754 | — | 13,754 |
| Research and development | 9,697 | 4,603 | 14,300 |
| Research and development - related parties | 4,836 | — | 4,836 |
| General and administrative | 4,268 | 3,594 | 7,862 |
| Transaction costs | — | 502 | 502 |
| Total segment operating expenses | 34,764 | 8,699 | 43,463 |
| Loss from segment operations | (5,667) | (8,691) | (14,358) |
| Other segment (loss) income, net: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s gyre — selling general and administrative expense?
- Gyre Therapeutics, Inc. (GYRE) reported gyre — selling general and administrative expense of $3.59M in Q2 2026.
- What does gyre — selling general and administrative expense mean?
- This metric captures the overhead costs associated with the business segment, including administrative salaries, legal fees, marketing, and general corporate support. It measures the operational efficiency of the segment's non-research functions and its ability to manage corporate infrastructure. High levels relative to revenue may indicate scaling challenges or high administrative burden.
Ask your AI about Gyre Therapeutics, Inc.'s gyre — selling general and administrative expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude